Clinical trials: Conventional therapy
Rheumatoid Arthritis
Open-Label Study Comparing Etanercept to Conventional Disease Modifying Antirheumatic Drug (DMARD) Therapy
The purpose of this 2 phased, open-label study is to compare the safety and efficacy of etanercept with conventional Disease Modifying Antirheumatic Drug (DMARD) therapy in Latin American subjects with moderate to severe…
- Trial name
- NCT00848354
- Testing
- Phase 1: Etanercept, Phase 1: Methotrexate, Phase 2: Optional ETN, SSZ, HCQ, MTX
- Where
- 33 sites in Argentina, Chile and 3 more
- Volunteers
- 429 people
- Sponsor
- Pfizer
Hypertension, Pulmonary
Pulmonary Hypertension: Assessment of Cell Therapy
The primary objective is to establish the safety of autologous progenitor cell-based gene therapy of heNOS in patients with severe Pulmonary Arterial Hypertension(PAH) refractory to conventional treatment.
- Trial name
- PHACeT (NCT00469027)
- Testing
- eNOS transfected EPCs will be delivered via a PA line
- Where
- 2 sites in Canada
- Volunteers
- 7 people
- Sponsor
- Northern Therapeutics
Classical Hodgkin's Lymphoma
Study of GLS-010 Injection in the Treatment of Classical Hodgkin's Lymphoma
Patients with refractory cHL. Patients will be treated with GLS-010
- Trial name
- NCT03655483
- Testing
- GLS-010
- Where
- 5 sites in China
- Volunteers
- 85 people
- Sponsor
- Guangzhou Gloria Biosciences Co., Ltd.
Bipolar Disorder
A Study in the Treatment of Acute Mania
The purpose of this study is to test the efficacy and total costs of olanzapine versus commonly used conventional antipsychotics in Sweden.
- Trial name
- NCT00767715
- Testing
- olanzapine, haloperidol, zuclopentixol
- Where
- Sweden
- Volunteers
- 11 people
- Sponsor
- Eli Lilly and Company
Dystrophic Epidermolysis Bullosa
Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa
After confirming eligibility, a single subject with four selected target lesions will receive both ALLO-ASC-SHEET and Vehicle control, three target lesions for ALLO-ASC-SHEET and the other target for Vehicle control, and which…
- Trial name
- NCT05157958
- Testing
- ALLO-ASC-SHEET, Vehicle Control
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Anterogen Co., Ltd.
Colon Cancer
Synergistic Anti-tumor Effect of ChangTai Keli for Colon Cancer Patients
The aim of this study is to evaluate the synergistic anti-tumor effect of ChangTai Keli based on chemotherapy for colon cancer patients by a randomized, parallel-group, double-blind, multicenter clinical study.
- Trial name
- NCT02510118
- Testing
- mFOLFOX6, XELOX, ChangTai Keli
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Nanjing NingQi Medicine Science and Technology Co., Ltd.
Crohn's Disease
A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies
The objective of this study is to evaluate the efficacy and safety of upadacitinib compared to placebo as induction therapy in adults with moderately and severely active Crohn's disease (CD).
- Trial name
- U-EXCEL (NCT03345849)
- Testing
- Upadacitinib
- Where
- 432 sites in United States, Argentina and 47 more
- Volunteers
- 526 people
- Sponsor
- AbbVie
Eosinophilic Asthma
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment
This study evaluates the efficacy and safety of benralizumab as an add-on therapy in uncontrolled eosinophilic asthma participants treated with medium-dose ICS-LABA compared to the conventional treatment step of escalation of…
- Trial name
- BRISOTE (NCT06750289)
- Testing
- ICS-LABA, benralizumab
- Where
- 86 sites in United States, Bulgaria and 11 more
- Volunteers
- 130 people
- Sponsor
- AstraZeneca
Leukemia, Acute Lymphoblastic
Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)
B-precursor ALL is an aggressive malignant disease. Therapy is usually stratified according to risk characteristics to ensure that appropriate treatment is administered to patients with high-risk of relapse.
- Trial name
- NCT02393859
- Testing
- Blinatumomab, Dexamethasone, Vincrisitne
- Where
- 103 sites in Argentina, Australia and 22 more
- Volunteers
- 111 people
- Sponsor
- Amgen
Arthritis, Rheumatoid
Study in Patients With Moderated to Severe Rheumatoid Arthritis Who Have Failed to Combination Therapy of Conventional Disease-modifying Antirheumatic Drugs (cDMARDs) to cDMARD Plus ANti-TNF Versus cDMARDs in Real World
This study will be conducted to observe the disease activity change of Conventional Disease Modifying Anti-Rheumatic Drugs (cDMARD) plus anti-tumour necrosis factor (anti-TNF) from baseline to 6 months compared with cDMARDs, as…
- Trial name
- HUMAN (NCT03264703)
- Where
- 15 sites in South Korea
- Volunteers
- 212 people
- Sponsor
- Eisai Korea Inc.
Bacterial Keratitis
Prospective, Randomized Multi-Center Study of Using the Hyper-CL™ Lens in Subjects Suffering From Bacterial Keratitis
This study is a prospective, randomized, open-label, two arms, clinical study aim to evaluate the efficacy and safety of treatment with Hyper-CL™ lens + Antibiotics compared with treatment with Antibiotics only, in subjects with…
- Trial name
- NCT03845374
- Testing
- Hyper-CL™ lens
- Where
- 2 sites in Israel
- Volunteers
- 12 people
- Sponsor
- Eye-yon Medical
Critical Limb Ischemia
The DES BTK Vascular Stent System vs PTA in Subjects With Critical Limb Ischemia
Single phased global, prospective, multicenter clinical trial designed to demonstrate a superior patency rate and acceptable safety in below the knee arteries with lesions treated with the DES BTK Vascular Stent System vs.
- Trial name
- SAVAL (NCT03551496)
- Testing
- Drug Eluting Stent - Below the Knee, Standard PTA Control Arm
- Where
- 42 sites in United States, Belgium and 3 more
- Volunteers
- 201 people
- Sponsor
- Boston Scientific Corporation
Arthropathy of Hip
Evaluation of Implant Survival in Patients With a Pinnacle Ultamet Device in Conventional Total Hip Joint Replacement
The objective is to evaluate the implant survival rate for patients implanted with a PINNACLE® ULTAMET™ Metal-on-Metal implant for conventional total hip arthroplasty for the treatment of a severe hip disease and true femoral…
- Trial name
- NCT01684631
- Testing
- Total Hip arthroplasty
- Where
- 6 sites in France
- Volunteers
- 107 people
- Sponsor
- DePuy International
Type 1 Diabetes
Obtain a Good Blood Glucose Control With the Paradigm Real Time System
In this study, subjects with insufficient metabolic control despite optimized basal-bolus injection regimens were randomily assigned to either the Mini- Med Paradigm REAL-Time insulin pump (PRT), an insulin pump that can receive…
- Trial name
- RTD (NCT00441129)
- Testing
- Minimed paradigm Real Time Sytem, Minimed Paradigm 512/712 Insulin pump
- Where
- 8 sites in France
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Medtronic MiniMed, Inc.
Dystrophic Epidermolysis Bullosa
Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Dystrophic Epidermolysis Bullosa
This is a phase I/II open-label study to evaluate the efficacy and safety of ALLO-ASC-DFU in patients with Dystrophic Epidermolysis Bullosa.
- Trial name
- NCT02579369
- Testing
- Allogeneic mesenchymal stem cells, Polyurethene Film
- Where
- South Korea
- Volunteers
- 2 people
- Sponsor
- Anterogen Co., Ltd.
Hypoparathyroidism
A Registry for Participants With Chronic Hypoparathyroidism
The main aim of this study is to find out the long-term safety and effectiveness profile of recombinant human parathyroid hormone (1-84) (rhPTH[1-84]) treatment in participants with chronic hypoparathyroidism under conditions of…
- Trial name
- PARADIGHM (NCT01922440)
- Testing
- No intervention
- Where
- 100 sites in United States, Austria and 9 more
- Volunteers
- 1,339 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 2
Insulin Glulisine in Diabetes Mellitus, Type 2
Primary objective: The primary study objective is to demonstrate superior efficacy of an intensified insulin regimen with insulin glulisine and insulin glargine to a two-injection conventional insulin regimen in terms of change…
- Trial name
- GINGER (NCT00174668)
- Testing
- Insulin Glulisine, Insulin Therapy, Insulin Glargine
- Where
- 15 sites in Australia, Belgium and 13 more
- Volunteers
- 311 people
- Sponsor
- Sanofi
Cataract, Astigmatism
Astigmatism Correction With Intrastromal Arcuate Incisions in Eyes Undergoing Cataract Surgery With Femtosecond Laser Using the Cassini Ambient With Iris Registration (ARCUATAS)
This is an observational, prospective follow-up post-marketing study of CE marked medical devices aimed at treating astigmatism in patients with cataracts.
- Trial name
- ARCUATAS (NCT05053620)
- Testing
- Calculation of the arcuate intrasomal incisions
- Where
- Spain
- Volunteers
- 22 people
- Sponsor
- OFTALVIST (Oftalmología Vistahermosa S.L)
Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis
Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,
This was a multi-center, randomized, active-controlled, open-label study. Approximately 24 patients with active, non-infectious intermediate-, posterior-, or panuveitis requiring systemic immunosuppressive therapy were enrolled.
- Conditions
- Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis, Non-infectious Panuveitis
- Trial name
- NCT01526889
- Testing
- LFG316, Conventional Therapy
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals
Sleep Apnea, Obstructive
Comparison Study of the ICON™ Auto Series With and Without SensAwake™ and ThermoSmart™ and Conventional Continuous Positive Airway Pressure in Obstructive Sleep Apnea Patients
A total of 216 patients will be randomized into a partially single blind, randomized, parallel-arm trial to determine whether the ICON™ AT with SensAwake™ and ThermoSmart™ can improve therapy adherence when compared to standard…
- Trial name
- NCT01517763
- Testing
- Conventional CPAP Therapy, Fixed pressure ICON™ without ThermoSmart™, Auto ICON™ with SensAwake™ and ThermoSmart™
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Fisher and Paykel Healthcare